MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.cct.2023.107358

Медицинская библиотека · Contemporary clinical trials · 2023

Rationale and design of Non-antithrombotic Therapy After Transcatheter Aortic Valve Implantation (NAPT) Trial.

Inohara Taku, Otsuka Toshiaki, Watanabe Yusuke, Shirai Shinichi, Tada Norio, Yamanaka Futoshi, Ueno Hiroshi, Ohno Yohei, Tabata Minoru, Suzuyama Hiroto, Asami Masahiko, Yamawaki Masahiro, Izumo Masaki, Yamasaki Kazumasa, Nishina Hidetaka, Fuku Yasushi, Mizutani Kazuki, Yashima Fumiaki, Yamamoto Masanori, Hayashida Kentaro

СтатьяПоддержка исследования: вне правительства СШАПротокол клинического исследованияПеревод в очереди

Аннотация

BACKGROUND

Despite the wide implementation of transcatheter aortic valve implantation (TAVI), the optimal antithrombotic therapy after TAVI has not been established yet. Owing to the accumulating evidence supporting the efficacy and safety of single antiplatelet therapy (SAPT) over dual antiplatelet therapy, the latest guideline recommends life-long SAPT. However, there is scarce evidence supporting SAPT compared with non-antithrombotic therapy. Given the vulnerability of patients undergoing TAVI in terms of high bleeding risk, the benefit of SAPT may be canceled out by its potential increased bleeding risk.

STUDY DESIGN AND

OBJECTIVES

Non-antithrombotic Therapy After Transcatheter Aortic Valve Implantation (NAPT) Trial is a prospective, randomized controlled, open-label blinded endpoint multicenter trial conducted in Japan, testing the non-inferiority of non-antithrombotic therapy compared with aspirin monotherapy in patients who underwent TAVI and had no indications for long-term oral anticoagulation therapy (OAC). Patients who successfully underwent trans-femoral TAVI for severe aortic stenosis with either balloon-expandable or self-expandable valves are eligible for inclusion. Key exclusion criteria are (i) occurrence of perioperative complications (ii) indications of taking antithrombotic drugs for other reasons; (iii) eGFR <30 ml/min/1.73 m2 or hemodialysis or peritoneal dialysis. A total of 360 patients will be randomized (1:1) to aspirin monotherapy vs. non-antithrombotic therapy. The primary outcome is a composite of all-cause mortality, myocardial infarction, stroke, and bleeding. All bleeding events based on the Valve Academic Research Consortium 3 are included as a component of the primary outcome.

CONCLUSION

The NAPT trial will determine the non-inferiority of a non-antithrombotic therapy compared with aspirin monotherapy after TAVI.

Для цитирования: Inohara Taku, Otsuka Toshiaki, Watanabe Yusuke, Shirai Shinichi, Tada Norio, Yamanaka Futoshi, Ueno Hiroshi, Ohno Yohei, Tabata Minoru, Suzuyama Hiroto, Asami Masahiko, Yamawaki Masahiro, Izumo Masaki, Yamasaki Kazumasa, Nishina Hidetaka, Fuku Yasushi, Mizutani Kazuki, Yashima Fumiaki, Yamamoto Masanori, Hayashida Kentaro. Rationale and design of Non-antithrombotic Therapy After Transcatheter Aortic Valve Implantation (NAPT) Trial.. Contemporary clinical trials. 2023. DOI: 10.1016/j.cct.2023.107358.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.